What is ChronoScale Holdings Corporation's earnings per share (EPS)?

ChronoScale Holdings Corporation (CHRN) reported diluted earnings per share of -$4.91 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ChronoScale Holdings Corporation (CHRN) Financials

CHRN

FY2026 annual

Revenue $12.8M -84.8% YoY

Net Income -$11.7M -3.2% YoY

EPS (Diluted) -$4.91 YoY not available

Free Cash Flow -$12.0M -21.3% YoY

Market Cap $2.7B as of Sep 16, 2026

Price / Sales 212x on $12.8M revenue, FY2026

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book n/m outside the range published as a multiple, on $2.1M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended May 31, 2026 Reported Aug 19, 2026 Currency USD FYE May

Newest figures come from the 10-K for FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CHRN SEC filings page.

ChronoScale Holdings Corporation (CHRN) reported $12.8M in revenue for fiscal year 2026, down 84.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CHRN FY2026 2026-08-30

ChronoScale's dominant mechanic is a large, non-debt-funded asset base paired with recurring operating cash consumption and weak short-term coverage.

Balance-sheet scale is detached from operating scale: in FY2026, $325.9M of assets supported only $12.8M of revenue, with $54.5M of goodwill representing a meaningful portion of that asset base. At the same time, cash conversion remains aligned with reported losses, as net income was -$11.7M and operating cash flow was -$11.8M, indicating little accounting-to-cash distortion.

Short-term liquidity is the main balance-sheet pressure: current assets of $44.2M were below current liabilities of $86.9M, producing a current ratio of 0.5x. That tight coverage contrasts with only $474K of long-term debt, so the liability burden is concentrated outside conventional long-term borrowing.

Operating costs absorb the gross profit base: FY2026 gross margin was 53.5%, yet operating margin was -104.1% because selling, general and administrative expense reached $19.8M. Revenue and margin also swung sharply from FY2025, when revenue was $84.4M and gross margin was 11.3%, pointing to an unstable revenue or mix structure rather than consistent scale benefits.

Financial Health Signals

Financial Health Score 26/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of ChronoScale Holdings Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

ChronoScale Holdings Corporation held $9.7M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $11.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and ChronoScale Holdings Corporation scores 29/100 among other emerging companies.

Dilution

ChronoScale Holdings Corporation had 146M shares outstanding at the end of fiscal year 2026. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and ChronoScale Holdings Corporation scores 6/100 among other emerging companies.

R&D Intensity

ChronoScale Holdings Corporation spent $3.0M on research and development in fiscal year 2026, which was 11.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and ChronoScale Holdings Corporation scores 38/100 among other emerging companies.

Revenue Progress

ChronoScale Holdings Corporation reported revenue of $12.8M in fiscal year 2026, against $84.4M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and ChronoScale Holdings Corporation scores 23/100 among other emerging companies.

Burn Trend

ChronoScale Holdings Corporation's operations used $11.8M of cash in fiscal year 2026, against $9.8M used in fiscal year 2025. Burn Trend ranks emerging companies on which way that figure has moved over three years, and ChronoScale Holdings Corporation scores 46/100 among other emerging companies.

Balance Sheet

ChronoScale Holdings Corporation's cash, cash equivalents and investments came to $9.7M at the end of fiscal year 2026, against $143.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and ChronoScale Holdings Corporation scores 12/100 among other emerging companies.

Altman Z-Score Safe

10.22

ChronoScale Holdings Corporation scores 10.22, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.7B) relative to total liabilities ($143.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

ChronoScale Holdings Corporation passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

ChronoScale Holdings Corporation reported a net loss of $11.7M while operations used $11.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

ChronoScale Holdings Corporation reported an operating loss of $13.3M against $309K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.1M

YoY-36.6%

ChronoScale Holdings Corporation generated $2.1M in revenue in Q4 2026. This represents a decrease of 36.6% from the same quarter a year earlier.

EBITDA

-$5.2M

YoY-68.6%

ChronoScale Holdings Corporation's EBITDA was -$5.2M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 68.6% from the same quarter a year earlier.

Net Income

-$6.9M

YoY-138.2%

ChronoScale Holdings Corporation reported -$6.9M in net income in Q4 2026. This represents a decrease of 138.2% from the same quarter a year earlier.

EPS (Diluted)

-$2.04

QoQ-30.8%

ChronoScale Holdings Corporation earned -$2.04 per diluted share (EPS) in Q4 2026. Against the prior quarter it is down 30.8%.

Cash & Balance Sheet

Free Cash Flow

-$2.1M

YoY-7.5%

QoQ+52.4%

ChronoScale Holdings Corporation recorded an outflow of $2.1M in free cash flow in Q4 2026, representing a cash shortfall after capex. This represents a decrease of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 52.4%.

Cash & Debt

$4.0M

YoY-50.4%

QoQ+241.6%

5Y CAGR-39.6%

10Y CAGR-10.7%

ChronoScale Holdings Corporation held $4.0M in cash as of Q4 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ0.0%

5Y CAGR-22.4%

10Y CAGR-14.0%

ChronoScale Holdings Corporation had 4M shares outstanding in Q4 2026. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q4 2026.

Margins & Returns

Gross Margin

50.2%

YoY-3.3pp

ChronoScale Holdings Corporation's gross margin was 50.2% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is down 3.3 percentage points from the same quarter a year earlier.

Return on Equity

-329.4%

YoY-306.6pp

ChronoScale Holdings Corporation's ROE was -329.4% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is down 306.6 percentage points from the same quarter a year earlier.

Operating Margin

Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q4 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$583K

YoY-41.0%

ChronoScale Holdings Corporation invested $583K in research and development in Q4 2026. This represents a decrease of 41.0% from the same quarter a year earlier.

Capital Expenditures

YoY-100.0%

QoQ-100.0%

ChronoScale Holdings Corporation reported no capital expenditure in Q4 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q4 2026.

CHRN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CHRN quarterly income statement

Metric	FY2610-K	FY2510-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$12.8M-84.8%	$84.4M	$18.3M+41.6%	$12.9M+14.8%	$11.2M+26.6%	$8.9M-36.2%	$13.9M+22.8%	$11.3M+54.1%	$7.4M-48.3%	$14.2M+64.2%	$8.7M+62.6%	$5.3M+61.3%	$3.3M	N/A
Cost of Revenue	$6.0M-29.2%	$8.4M	$9.2M+37.4%	$6.7M+48.9%	$4.5M+18.0%	$3.8M-46.7%	$7.2M+1.9%	$7.0M+32.9%	$5.3M-53.1%	$11.3M+50.7%	$7.5M+98.6%	$3.8M+38.8%	$2.7M	N/A
Gross Profit	$6.8M-28.0%	$9.5M	$9.1M+46.1%	$6.2M-7.9%	$6.7M+33.1%	$5.1M-25.0%	$6.8M+57.0%	$4.3M+108.3%	$2.1M-29.8%	$2.9M+150.0%	$1.2M-24.4%	$1.6M+165.6%	$587K	N/A
R&D Expenses	$3.0M-21.8%	$3.9M	$5.0M+38.6%	$3.6M+42.3%	$2.5M+3.0%	$2.5M-46.2%	$4.6M-21.4%	$5.8M-38.3%	$9.5M+6.8%	$8.9M+37.0%	$6.5M+67.5%	$3.9M+44.5%	$2.7M	N/A
SG&A Expenses	$19.8M-20.2%	$24.8M	$10.7M-2.7%	$11.0M+2.5%	$10.7M+39.2%	$7.7M+4.0%	$7.4M-36.5%	$11.7M+8.9%	$10.7M-1.3%	$10.9M+55.0%	$7.0M-5.4%	$7.4M+89.1%	$3.9M+289537.3%	$1K
Operating Income	-$13.3M-27.4%	-$10.5M	-$15.1M+2.9%	-$15.6M-12.5%	-$13.8M-4.0%	-$13.3M+20.1%	-$16.6M+38.4%	-$27.0M+14.5%	-$31.6M-14.6%	-$27.6M-27.9%	-$21.6M-28.4%	-$16.8M-63.1%	-$10.3M	N/A
EBITDA	-$11.8M-32.8%	-$8.9M	-$13.4M+8.6%	-$14.7M-14.6%	-$12.8M-1.1%	-$12.7M+20.6%	-$15.9M+38.7%	-$26.0M+14.4%	-$30.4M-18.2%	-$25.7M-24.7%	-$20.6M-28.5%	-$16.0M-63.3%	-$9.8M	N/A
Interest Expense	$309K+14.9%	$269K	$302K+93.6%	$156K+38.1%	$113K-18.7%	$139K-63.8%	$384K-36.0%	$600K-7.4%	$648K+3950.0%	$16K+23.1%	$13K-97.0%	$435K-74.8%	$1.7M	N/A
Income Tax	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$11.7M-3.2%	-$11.3M	-$15.2M-0.8%	-$15.1M-54.4%	-$9.8M+38.3%	-$15.8M-30.4%	-$12.1M+55.1%	-$27.0M+7.3%	-$29.1M-24.1%	-$23.5M-19.8%	-$19.6M+42.0%	-$33.8M-184.1%	-$11.9M	N/A
EPS (Basic)	-$4.91+41.8%	-$8.43	-$1.10+5.2%	-$1.16-45.0%	-$0.80+63.8%	-$2.21+12.6%	-$2.53-475.0%	-$0.44+46.3%	-$0.82+56.1%	-$1.87-12.7%	-$1.66+45.0%	-$3.02-429.8%	-$0.57	N/A
EPS (Diluted)	-$4.91	-$8.43	-$1.10+5.2%	-$1.16-31.8%	-$0.88	-$2.21	-$2.53	-$0.44	-$0.82	-$2.05	-$1.83+39.4%	-$3.02	-$0.57	N/A
Diluted Shares (Avg)	139M	20M	14M+7.0%	13M+5.6%	12M	7M	5M	61M	36M	19M	15M+30.7%	11M	21M	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Revenue	$2.1M-36.6%	N/A	$4.2M+2.4%	$2.1M-58.4%	$3.4M-10.1%	$74.8M+1443.5%	$4.1M-10.4%	$5.0M+5.3%
Cost of Revenue	$1.1M-32.0%	N/A	$1.7M-12.6%	$1.2M-46.5%	$1.6M-13.1%	$3.7M+48.8%	$1.9M-10.7%	$2.3M-5.6%
Gross Profit	$1.1M-40.5%	N/A	$2.5M+15.4%	$819K-68.9%	$1.8M-7.4%	$4.7M+97.4%	$2.2M-10.1%	$2.6M+17.0%
R&D Expenses	$583K-41.0%	N/A	$550K-29.2%	$852K-23.7%	$988K-13.0%	$1.3M-4.3%	$777K-33.0%	$1.1M-20.2%
SG&A Expenses	$4.1M+59.1%	N/A	$2.1M-9.6%	$2.3M+12.0%	$2.6M+13.2%	$17.7M+602.1%	$2.3M+6.2%	$2.0M-28.0%
Operating Income	-$5.6M-63.3%	N/A	-$1.4M+46.9%	-$4.0M-70.2%	-$3.4M-5.7%	-$406K+88.2%	-$2.6M+10.0%	-$2.3M+45.5%
EBITDA	-$5.2M-68.6%	N/A	-$1.0M+53.6%	-$3.6M-85.7%	-$3.1M-7.4%	$40K+101.3%	-$2.2M+11.0%	-$1.9M+49.7%
Interest Expense	$143K+98.6%	N/A	$18K-77.2%	$65K-12.2%	$72K+26.3%	$53K-18.5%	$79K+23.4%	$74K+21.3%
Net Income	-$6.9M-138.2%	N/A	-$1.4M+31.4%	-$2.7M-12.1%	-$2.9M+15.7%	-$3.7M-13.8%	-$2.1M+38.4%	-$2.4M+42.9%
EPS (Basic)	-$2.04-10.9%	-$1.56+24.3%	-$0.54+64.7%	-$1.24+37.7%	-$1.84-820.0%	-$2.06-836.4%	-$1.53-537.5%	-$1.99-541.9%
EPS (Diluted)	-$2.04	-$1.56	-$0.54	-$1.24	-$1.84	-$2.06	-$1.53	-$1.99
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	20M	18M

Not reported in any period shown, so not listed: Income Tax.

CHRN Balance Sheet

CHRN quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$325.9M+1306.6%	$23.2M	$28.9M-29.3%	$40.9M-16.8%	$49.2M+138.7%	$20.6M-6.0%	$21.9M+24.1%	$17.7M-53.5%	$38.0M+55.5%	$24.4M-24.1%	$32.2M-3.8%	$33.5M+408.4%	$6.6M+21883.3%	$30K
Current Assets	$44.2M+177.0%	$16.0M	$20.2M-34.9%	$31.0M-35.1%	$47.8M+159.5%	$18.4M-2.1%	$18.8M+25.7%	$15.0M-57.2%	$34.9M+68.9%	$20.7M-17.9%	$25.2M-14.0%	$29.3M+814.8%	$3.2M	N/A
Cash & Equivalents	$9.7M+84.4%	$5.2M	$8.6M-57.9%	$20.5M-49.2%	$40.4M+214.2%	$12.9M+18.3%	$10.9M+42.0%	$7.7M-72.5%	$27.8M+65.1%	$16.8M-13.8%	$19.6M-22.4%	$25.2M+3029.2%	$805K	N/A
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Inventory	N/A	$5.4M	$5.0M-2.6%	$5.2M+131.4%	$2.2M+13.3%	$2.0M-20.5%	$2.5M-26.2%	$3.4M+11.4%	$3.0M+94.4%	$1.6M+47.3%	$1.1M+69.8%	$622K-14.2%	$725K	N/A
Accounts Receivable	$12.5M+176.7%	$4.5M	$5.6M+22.1%	$4.6M-0.8%	$4.7M+44.6%	$3.2M-38.1%	$5.2M+42.3%	$3.7M+32.6%	$2.8M+55.1%	$1.8M-14.0%	$2.1M+33.6%	$1.5M+182.1%	$549K	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Goodwill	$54.5M+12548.0%	$431K	$431K0.0%	$431K	$0	$0-100.0%	$189K0.0%	$189K0.0%	$189K0.0%	$189K0.0%	$189K	$0	N/A	N/A
Total Liabilities	$143.8M+1075.4%	$12.2M	$16.3M+5.5%	$15.5M+29.4%	$11.9M-26.1%	$16.2M+6.9%	$15.1M+1.3%	$14.9M-10.1%	$16.6M-7.2%	$17.9M-23.5%	$23.4M+119.1%	$10.7M-75.2%	$43.0M+71.0%	$25.1M
Current Liabilities	$86.9M+1194.2%	$6.7M	$8.1M-11.8%	$9.2M+34.2%	$6.9M+37.8%	$5.0M-36.5%	$7.8M-22.3%	$10.1M+10.0%	$9.2M+44.8%	$6.3M-26.6%	$8.6M+30.3%	$6.6M-45.1%	$12.1M	N/A
Non-Current Liabilities	$56.9M+931.1%	$5.5M	$8.2M+30.9%	$6.3M+22.9%	$5.1M-54.5%	$11.2M+53.6%	$7.3M+50.3%	$4.8M-34.8%	$7.4M-35.7%	$11.6M-21.7%	$14.8M+263.8%	$4.1M-86.9%	$30.9M	N/A
Long-Term Debt	$474K-96.0%	$12.0M	N/A	N/A	$2.0M+0.2%	$2.0M+388.7%	$407K-84.6%	$2.6M-45.2%	$4.8M+2996.2%	$156K-36.6%	$246K+90.7%	$129K	N/A	N/A
Total Equity	$180.0M+1547.1%	$10.9M	$12.6M-50.5%	$25.4M-31.6%	$37.2M+739.4%	$4.4M-34.8%	$6.8M+149.2%	$2.7M-87.2%	$21.4M+227.5%	$6.5M-25.9%	$8.8M-61.4%	$22.8M+162.7%	-$36.4M-45.0%	-$25.1M
Retained Earnings	-$199.5M+22.2%	-$256.3M	-$239.1M-6.8%	-$223.9M-7.2%	-$208.9M-4.9%	-$199.1M-8.6%	-$183.3M-7.1%	-$171.1M-18.7%	-$144.2M-25.5%	-$114.9M-25.7%	-$91.4M-27.3%	-$71.8M-88.8%	-$38.0M	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Total Assets	$19.7M-28.0%	$20.1M-24.5%	$21.7M-25.8%	$23.2M-14.1%	$27.3M-5.7%	$26.7M-7.8%	$29.2M-6.3%	$27.0M-20.6%
Current Assets	$14.1M-30.0%	$14.0M-25.4%	$14.8M-29.8%	$16.0M-14.3%	$20.1M-2.2%	$18.8M-6.8%	$21.1M-5.8%	$18.6M-24.6%
Cash & Equivalents	$4.0M-50.4%	$1.2M-74.0%	$2.7M-67.2%	$5.2M-10.9%	$8.1M-8.5%	$4.5M-48.0%	$8.3M-16.6%	$5.9M-55.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$4.6M-6.3%	$4.8M+5.5%	$5.0M-0.2%	$5.4M+9.3%	$5.0M-2.8%	$4.6M-9.5%	$5.0M-8.3%	$5.0M-11.2%
Accounts Receivable	$4.5M-29.7%	$7.3M+1.0%	$6.0M-13.2%	$4.5M-30.5%	$6.5M-10.8%	$7.2M+28.2%	$7.0M+18.6%	$6.5M+29.1%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%	$431K0.0%
Total Liabilities	$13.9M-4.7%	$11.1M-20.5%	$12.0M-16.4%	$12.2M-18.0%	$14.6M-1.9%	$13.9M-14.5%	$14.3M-10.0%	$14.9M-7.8%
Current Liabilities	$9.1M+6.3%	$8.6M+14.6%	$8.9M+19.1%	$6.7M-12.9%	$8.6M+17.0%	$7.5M-7.1%	$7.5M-4.2%	$7.7M-23.9%
Non-Current Liabilities	$4.8M-20.2%	$2.4M-61.8%	$3.0M-55.5%	$5.5M-23.5%	$6.1M-20.1%	$6.4M-21.8%	$6.8M-15.6%	$7.2M+19.4%
Long-Term Debt	N/A	N/A	N/A	$12.0M	N/A	N/A	N/A	N/A
Total Equity	$2.1M-83.5%	$9.0M-29.0%	$9.7M-34.9%	$10.9M-9.4%	$12.7M-9.7%	$12.7M+0.8%	$14.9M-2.5%	$12.1M-32.3%
Retained Earnings	-$269.3M-6.2%	-$262.4M-4.8%	-$257.7M-4.3%	-$256.3M-4.6%	-$253.6M-4.5%	-$250.5M-4.7%	-$247.1M-4.7%	-$245.0M-5.3%

CHRN Cash Flow Statement

CHRN quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$11.8M-19.9%	-$9.8M	-$12.1M+17.9%	-$14.7M-31.7%	-$11.2M-27.4%	-$8.8M+44.5%	-$15.8M+28.8%	-$22.2M+29.0%	-$31.2M-24.9%	-$25.0M-36.8%	-$18.3M-21.7%	-$15.0M-65.6%	-$9.1M	N/A
Depreciation & Amortization	$1.6M-2.2%	$1.6M	$1.7M+91.4%	$887K-13.3%	$1.0M+65.0%	$620K-10.1%	$690K-31.6%	$1.0M-15.7%	$1.2M-35.5%	$1.9M+98.8%	$933K+25.2%	$745K+58.8%	$469K	N/A
Stock-Based Compensation	$1.5M+7.4%	$1.4M	$1.9M-27.0%	$2.5M+9.3%	$2.3M-3.4%	$2.4M+6.9%	$2.3M-21.4%	$2.9M+18.8%	$2.4M-22.7%	$3.1M+80.3%	$1.7M+51.4%	$1.1M+192.3%	$391K+17.4%	$333K
Capital Expenditures	$188K+408.1%	$37K	$157K-19.1%	$194K+228.8%	$59K	$0-100.0%	$60K-54.2%	$131K-71.3%	$456K-58.4%	$1.1M-26.5%	$1.5M+0.3%	$1.5M+292.3%	$379K	N/A
Free Cash Flow	-$12.0M-21.3%	-$9.9M	-$12.2M+17.9%	-$14.9M-32.7%	-$11.2M-28.1%	-$8.8M+44.7%	-$15.8M+29.0%	-$22.3M+29.6%	-$31.7M-21.4%	-$26.1M-32.0%	-$19.8M-19.8%	-$16.5M-74.7%	-$9.4M	N/A
Investing Cash Flow	-$188K-408.1%	-$37K	-$157K+97.0%	-$5.2M-8671.2%	-$59K	$0+100.0%	-$60K+54.2%	-$131K+71.3%	-$456K+58.4%	-$1.1M+26.5%	-$1.5M	N/A	N/A	N/A
Financing Cash Flow	$6.6M-14.7%	$7.8M	$348K	$0-100.0%	$38.7M+261.7%	$10.7M-43.8%	$19.0M+737.6%	$2.3M-94.7%	$42.6M+82.6%	$23.3M+65.0%	$14.1M	N/A	N/A	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Operating Cash Flow	-$2.1M-8.0%	-$4.3M-202.2%	-$2.1M+9.5%	-$3.4M-29.0%	-$2.0M+43.3%	-$1.4M+9.5%	-$2.3M+32.1%	-$2.7M+8.0%
Depreciation & Amortization	$454K+20.1%	$451K+13.3%	$367K-9.8%	$377K-5.0%	$378K-6.9%	$398K-7.9%	$407K-4.0%	$397K-7.2%
Stock-Based Compensation	$114K-54.4%	N/A	$234K-42.4%	$207K-27.4%	$250K-33.5%	N/A	$406K-7.9%	$285K-44.6%
Capital Expenditures	$0-100.0%	$126K+500.0%	$12K+50.0%	$40K	$10K+25.0%	$21K-51.2%	$8K-52.9%	$0-100.0%
Free Cash Flow	-$2.1M-7.5%	-$4.5M-206.5%	-$2.1M+9.3%	-$3.5M-30.5%	-$2.0M+43.1%	-$1.5M+10.6%	-$2.3M+32.2%	-$2.7M+9.7%
Investing Cash Flow	$0+100.0%	-$126K-500.0%	-$12K-50.0%	-$40K	-$10K-25.0%	-$21K+51.2%	-$8K+52.9%	$0+100.0%
Financing Cash Flow	$5.0M+40.3%	$2.9M+1030.3%	-$437K-109.3%	$616K+332.5%	$3.5M-3.5%	-$314K-190.2%	$4.7M	-$265K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CHRN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CHRN quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	53.5%+42.2pp	11.3%	49.7%+1.5pp	48.1%-11.9pp	60.0%+2.9pp	57.1%+8.5pp	48.6%+10.6pp	38.0%+9.9pp	28.1%+7.4pp	20.7%+7.1pp	13.6%-15.7pp	29.3%+11.5pp	17.8%	N/A
Operating Margin	-104.1%	-12.4%	-82.7%	-120.5%	-123.0%	-149.6%	-119.6%	-238.5%	-429.9%	-194.0%	-248.9%	-315.3%	-311.8%	N/A
Net Margin	-91.4%-77.9pp	-13.4%	-83.1%	-116.8%	-86.8%	-178.2%	-87.2%	-238.2%	-396.1%	-165.0%	-226.2%	-633.9%	-360.0%	N/A
Return on Equity	-6.5%+97.2pp	-103.7%	-120.6%-61.3pp	-59.3%-33.0pp	-26.2%+330.7pp	-356.9%-178.4pp	-178.5%+810.9pp	-989.4%-853.3pp	-136.1%+223.2pp	-359.4%-136.9pp	-222.4%-74.3pp	-148.1%	N/A	N/A
Return on Assets	-3.6%+45.3pp	-48.9%	-52.6%-15.7pp	-36.9%-17.0pp	-19.9%+57.0pp	-76.8%-21.5pp	-55.4%+97.5pp	-152.9%-76.2pp	-76.7%+19.4pp	-96.1%-35.2pp	-60.8%+40.0pp	-100.9%+79.7pp	-180.5%	N/A
Current Ratio	0.51-1.9x	2.38	2.49-0.9x	3.37-3.6x	6.97+3.3x	3.70+1.3x	2.40+0.9x	1.48-2.3x	3.81+0.5x	3.27+0.3x	2.92-1.5x	4.43+4.2x	0.27	N/A
Debt-to-Equity	0.00-1.1x	1.10	1.29+0.7x	0.61+0.6x	0.05-0.4x	0.45+0.4x	0.06-0.9x	0.97+0.7x	0.23+0.2x	0.020.0x	0.030.0x	0.01	N/A	N/A
Asset Turnover	0.04-3.6x	3.64	0.63+0.3x	0.32+0.1x	0.23-0.2x	0.43-0.2x	0.640.0x	0.64+0.4x	0.19-0.4x	0.58+0.3x	0.27+0.1x	0.16-0.3x	0.50	N/A
FCF Margin	-93.7%-82.0pp	-11.7%	-66.8%	-115.3%	-99.7%-1.1pp	-98.6%	-113.8%	-196.8%	-430.9%	-183.5%	-228.2%	-309.6%	-285.9%	N/A

Metric	Q4'2610-K	Q3'2610-K	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Gross Margin	50.2%-3.3pp	N/A	60.3%+6.8pp	39.8%-13.4pp	53.5%+1.6pp	6.3%-42.6pp	53.5%+0.2pp	53.3%+5.3pp
Operating Margin	-262.4%	N/A	-33.2%+30.7pp	-193.2%	-101.9%	-0.5%+70.6pp	-63.9%-0.3pp	-47.2%+43.9pp
Net Margin	-321.6%	N/A	-33.6%+16.6pp	-131.7%	-85.7%+5.6pp	-4.9%+61.4pp	-50.2%+22.9pp	-48.8%+41.1pp
Return on Equity	-329.4%-306.6pp	N/A	-14.7%-0.8pp	-24.8%-4.7pp	-22.8%+1.6pp	-28.8%-3.3pp	-13.9%+8.1pp	-20.0%+3.7pp
Return on Assets	-35.0%-24.4pp	N/A	-6.6%+0.5pp	-11.7%-2.7pp	-10.6%+1.3pp	-13.7%-2.6pp	-7.1%+3.7pp	-8.9%+3.5pp
Current Ratio	1.55-0.8x	1.63-0.9x	1.66-1.2x	2.380.0x	2.35-0.5x	2.500.0x	2.810.0x	2.420.0x
Debt-to-Equity	6.66+5.5x	1.23+0.1x	1.24+0.3x	1.10-0.1x	1.15+0.1x	1.10-0.2x	0.96-0.1x	1.24+0.3x
Asset Turnover	0.110.0x	N/A	0.20+0.1x	0.09-0.1x	0.120.0x	2.81+2.6x	0.140.0x	0.180.0x
FCF Margin	-99.2%-40.6pp	N/A	-49.0%+6.3pp	-169.4%	-58.5%+34.0pp	-1.9%+31.6pp	-55.3%+17.8pp	-53.9%+9.0pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.51), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Where ChronoScale Holdings Corporation Ranks

Frequently Asked Questions

What is ChronoScale Holdings Corporation's annual revenue?

ChronoScale Holdings Corporation (CHRN) reported $12.8M in total revenue for fiscal year 2026. This represents a -84.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ChronoScale Holdings Corporation's revenue growing?

ChronoScale Holdings Corporation (CHRN) revenue declined by 84.8% year-over-year, from $84.4M to $12.8M in fiscal year 2026.

Is ChronoScale Holdings Corporation profitable?

No, ChronoScale Holdings Corporation (CHRN) reported a net income of -$11.7M in fiscal year 2026, with a net profit margin of -91.4%.

What is ChronoScale Holdings Corporation's EBITDA?

ChronoScale Holdings Corporation (CHRN) had EBITDA of -$11.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does ChronoScale Holdings Corporation have?

As of fiscal year 2026, ChronoScale Holdings Corporation (CHRN) had $9.7M in cash and equivalents against $474K in long-term debt.

What is ChronoScale Holdings Corporation's gross margin?

ChronoScale Holdings Corporation (CHRN) had a gross margin of 53.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is ChronoScale Holdings Corporation's net profit margin?

ChronoScale Holdings Corporation (CHRN) had a net profit margin of -91.4% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is ChronoScale Holdings Corporation's return on equity (ROE)?

ChronoScale Holdings Corporation (CHRN) has a return on equity of -6.5% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is ChronoScale Holdings Corporation's free cash flow?

ChronoScale Holdings Corporation (CHRN) recorded an outflow of $12.0M in free cash flow during fiscal year 2026. This represents a -21.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ChronoScale Holdings Corporation's operating cash flow?

ChronoScale Holdings Corporation (CHRN) recorded an outflow of $11.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are ChronoScale Holdings Corporation's total assets?

ChronoScale Holdings Corporation (CHRN) had $325.9M in total assets as of fiscal year 2026, including both current and long-term assets.

What are ChronoScale Holdings Corporation's capital expenditures?

ChronoScale Holdings Corporation (CHRN) invested $188K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does ChronoScale Holdings Corporation spend on research and development?

ChronoScale Holdings Corporation (CHRN) invested $3.0M in research and development during fiscal year 2026.

How many shares does ChronoScale Holdings Corporation have outstanding?

ChronoScale Holdings Corporation (CHRN) had 146M shares outstanding as of fiscal year 2026.

What is ChronoScale Holdings Corporation's current ratio?

ChronoScale Holdings Corporation (CHRN) had a current ratio of 0.51 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

What is ChronoScale Holdings Corporation's debt-to-equity ratio?

ChronoScale Holdings Corporation (CHRN) had a debt-to-equity ratio of 0.00 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ChronoScale Holdings Corporation's return on assets (ROA)?

ChronoScale Holdings Corporation (CHRN) had a return on assets of -3.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is ChronoScale Holdings Corporation's P/E ratio?

ChronoScale Holdings Corporation (CHRN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $2.7B as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ChronoScale Holdings Corporation's price-to-sales ratio?

ChronoScale Holdings Corporation (CHRN) trades at 212x sales, its market capitalization divided by revenue of $12.8M revenue, FY2026. The market capitalization is $2.7B as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does ChronoScale Holdings Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, ChronoScale Holdings Corporation (CHRN) held $9.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $11.8M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is ChronoScale Holdings Corporation's Altman Z-Score?

ChronoScale Holdings Corporation (CHRN) has an Altman Z-Score of 10.22, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ChronoScale Holdings Corporation's Piotroski F-Score?

ChronoScale Holdings Corporation (CHRN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ChronoScale Holdings Corporation's earnings high quality?

ChronoScale Holdings Corporation (CHRN) reported a net loss of $11.7M while operations used $11.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ChronoScale Holdings Corporation cover its interest payments?

ChronoScale Holdings Corporation (CHRN) reported an operating loss of $13.3M against $309K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is ChronoScale Holdings Corporation?

ChronoScale Holdings Corporation (CHRN) scores 26 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.